Erratum: Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice (Journal of Clinical Investigation (2011) 121, 5 (1871-1881) DOI: 10.1172/JCI44393);Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice

Journal of Clinical Investigation

Volumn 121, Issue 5, 2011, Pages 1871-1881

  Chan, Aubrey C ^a   Drakos, Stavros G ^a   Ruiz, Oscar E ^a   Smith, Alexandra C H ^a   Gibson, Christopher C ^a,b   Ling, Jing ^a   Passi, Samuel F ^a   Stratman, Amber N ^c   Sacharidou, Anastasia ^c   Revelo, M Patricia ^a   Grossmann, Allie H ^a   Diakos, Nikolaos A ^a   Davis, George E ^c   Metzstein, Mark M ^a   Whitehead, Kevin J ^a   Li, Dean Y ^a,d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Department of Electrical and Computer Engineering   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAVERNOUS HEMANGIOMA; CCM2 GENE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; KRIT1 GENE; MALE; NONHUMAN; PDCD10 GENE; PHENOTYPE; PRIORITY JOURNAL;

EID: 79955516472     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63474     Document Type: Erratum

References (53)

1. Otten P, Pizzolato GP, Rilliet B, Berney J. A propos de 131 cas d'angiomes caverneux (cavernomes) du S.N.C. repérés par l'analyse rétrospective de 24 535 autopsies. Neurochirurgie. 1989;35(2):82-83. (Pubitemid 19143805)
2. Vernooij MW, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821-1828. (Pubitemid 350044802)
3. Hasegawa T, McInerney J, Kondziolka D, Lee JY, Flickinger JC, Lunsford LD. Long-term results after stereotactic radiosurgery for patients with cavernous malformations. Neurosurgery. 2002;50(6):1190-1197.
4. Chappell PM, Steinberg GK, Marks MP. Clinically documented hemorrhage in cerebral arteriovenous malformations: MR characteristics. Radiology. 1992;183(3):719-724.
5. Burger PC, Scheithauer BW. Tumors of the Central Nervous System. Washington, DC, USA: American Registry of Pathology; 2007.
6. Wang H, Gujrati M. Pathology of cerebral cavernous malformations. In: Lanzino G, Spetzler RF, eds. Cavernous Malformations of the Brain and Spinal Cord. New York, New York, USA: Thieme Medical Publishers, Inc; 2008:22-25.
7. Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformations: a complex jigsaw puzzle under construction. FEBS J. 2010;277(5):1084-1096.
8. Hilder TL, et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res. 2007;6(11):4343-4355. (Pubitemid 350158510)
9. Whitehead KJ, et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med. 2009;15(2):177-184.
10. Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development. 2004; 131(6):1437-1448. (Pubitemid 38443895)
11. Boulday G, et al. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech. 2009;2(3-4):168-177.
12. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010;207(4):881-896.
13. Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J Cell Biol. 2007; 179(2):247-254. (Pubitemid 350004889)
14. Borikova AL, et al. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem. 2010;285(16):11760- 11764.
15. Zawistowski JS, et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet. 2005;14(17):2521-2531. (Pubitemid 41236065)
16. Fidalgo M, Fraile M, Pires A, Force T, Pombo C, Zalvide J. CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci. 2010;123(pt 8):1274-1284.
17. Zhang J, Clatterbuck RE, Rigamonti D, Chang DD, Dietz HC. Interaction between krit1 and icap1alpha infers perturbation of integrin beta1- mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum Mol Genet. 2001;10(25):2953-2960. (Pubitemid 34030926)
18. Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet. 2002;11(4):389-396. (Pubitemid 34213612)
19. Uhlik MT, et al. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol. 2003;5(12):1104-1110. (Pubitemid 37509118)
20. Ma X, et al. PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway. Mol Biol Cell. 2007;18(6):1965-1978. (Pubitemid 46911350)
21. Voss K, et al. Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the way for domain mapping of the cerebral cavernous malformation 3 protein. Hum Mutat. 2009;30(6):1003-1011.
22. Goudreault M, et al. A PP2A phosphatase high-density interaction network identifies a novel striatininteracting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics. 2008;8(1):157-171.
23. Zheng X, et al. CCM3 signaling through sterile 20- like kinases plays an essential role during zebrafish cardiovascular development and cerebral cavernous malformations. J Clin Invest. 2010;120(8):2795-2804.
24. Denier C, et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol. 2006;60(5):550-556. (Pubitemid 44871797)
25. Sirvente J, Enjolras O, Wassef M, Tournier-Lasserve E, Labauge P. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol. 2009;23(9):1066-1072.
26. Labauge P, et al. Multiple dural lesions mimicking meningiomas in patients with CCM3/PDCD10 mutations. Neurology. 2009;72(23):2044-2046.
27. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet. 2009;18(5):919-930.
28. Gault J, et al. Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery. 2009;65(1):138-144.
29. Pagenstecher A, Stahl S, Sure U, Felbor U. A twohit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009;18(5):911-918.
30. Rigamonti D, et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med. 1988;319(6):343-347.
31. Labauge P, Brunereau L, Levy C, Laberge S, Houtteville JP. The natural history of familial cerebral cavernomas: a retrospective MRI study of 40 patients. Neuroradiology. 2000;42(5):327-332. (Pubitemid 30265347)
32. Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg. 1991;75(5):702-708.
33. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-823.
34. Gault J, Shenkar R, Recksiek P, Awad IA. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005;36(4):872-874.
35. Shenkar R, et al. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008;63(4):790-797.
36. McDonald DA, et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011;20(2):211-222.
37. Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M. Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis. 2008;46(2):74-80. (Pubitemid 351498176)
38. Davis GE, Camarillo CW. An alpha 2 beta 1 integrin- dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res. 1996;224(1):39-51. (Pubitemid 26116886)
39. Ghabrial A, Luschnig S, Metzstein MM, Krasnow MA. Branching morphogenesis of the Drosophila tracheal system. Annu Rev Cell Dev Biol. 2003;19:623-647. (Pubitemid 37487363)
40. Manning G, Krasnow MA. Development of the Drosophila tracheal system. In The Development of Drosophila melanogaster. Bate M, Martinez Arias A, eds. Plainview, New York, USA: Cold Spring Harbor Laboratory Press; 1993:609-685.
41. Mummery-Widmer JL, et al. Genome-wide analysis of Notch signalling in Drosophila by transgenic RNAi. Nature. 2009;458(7241):987-992.
42. Shiga Y, Tanaka-Matakatsu M, Hayashi S. A nuclear GFP/beta-galactosidase fusion protein as a marker for morphogenesis in living Drosophila. Dev Growth Differ. 1996;38(1):99-106. (Pubitemid 26061341)
43. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118(2):401-415. (Pubitemid 23214028)
44. Dietzl G, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature. 2007;448(7150):151-156. (Pubitemid 47067374)
45. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry. 2001;71(2):188-192. (Pubitemid 32675143)
46. Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med. 2010;152(8):513-520.
47. He Y, et al. Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal. 2010;3(116):ra26.
48. Navankasattusas S, et al. The netrin receptor UNC5B promotes angiogenesis in specific vascular beds. Development. 2008;135(4):659-667. (Pubitemid 351405019)
49. di Tomaso E, et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE. 2009;4(4):e5123.
50. Jones CA, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med. 2008;14(4):448-453. (Pubitemid 351499393)
51. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci. 2005;118(pt 10):2325-2340.
52. Groth AC, Fish M, Nusse R, Calos MP. Construction of transgenic Drosophila by using the sitespecific integrase from phage phiC31. Genetics. 2004;166(4):1775-1782. (Pubitemid 38621059)
53. Venken KJ, He Y, Hoskins RA, Bellen HJ. P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster. Science. 2006;314(5806):1747-1751. (Pubitemid 44969080)